Indication
Argininosuccinate lyase deficiency
Argininosuccinate lyase deficiency, also known as argininosuccinic aciduria, is an autosomal recessive urea cycle disorder caused by pathogenic variants in the *ASL* gene. Read more about Argininosuccinate lyase deficiency
12 drugs 12 manufacturers
Drugs that treat it
Common Argininosuccinate lyase deficiency therapies.
SODIUM PHENYLACET-SOD BENZOATE (sodium benzoate/sodium phenylacetate)
SODIUM PHENYLACET-SOD BENZOATE (sodium benzoate/sodium phenylacetate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonArgininosuccinate lyase deficiency, also known as argininosuccinic aciduria, is an autosomal recessive urea cycle disorder caused by pathogenic variants in the *ASL* gene.
This enzymatic defect impairs the conversion of argininosuccinate into arginine and fumarate, disrupting nitrogen detoxification and leading to systemic accumulations of argininosuccinic acid, citrulline, and neurotoxic ammonia.
Manifesting across pediatric and adult populations, the clinical spectrum ranges from catastrophic neonatal hyperammonemic encephalopathy to late-onset disease marked by episodic hyperammonemia, developmental delay, chronic liver dysfunction or cirrhosis, neurocognitive impairment, trichorrhexis nodosa, and systemic hypertension.
- nih.gov
Argininosuccinate lyase deficiency, also known as argininosuccinic aciduria, is an autosomal recessive urea cycle disorder caused by pathogenic variants in the *ASL* gene This enzymatic defect impairs the conversion of argininosuccinate into arginine and fumarate, disrupting nitrogen detoxification and leading to systemic accumulations of argininosuccinic acid, citrulline, and neurotoxic ammonia Manifesting across pediatric and adult populations, the clinical spectrum ranges from catastrophic ne...
- nih.gov
Argininosuccinate lyase deficiency, also known as argininosuccinic aciduria, is an autosomal recessive urea cycle disorder caused by pathogenic variants in the *ASL* gene This enzymatic defect impairs the conversion of argininosuccinate into arginine and fumarate, disrupting nitrogen detoxification and leading to systemic accumulations of argininosuccinic acid, citrulline, and neurotoxic ammonia
- nih.gov
Manifesting across pediatric and adult populations, the clinical spectrum ranges from catastrophic neonatal hyperammonemic encephalopathy to late-onset disease marked by episodic hyperammonemia, developmental delay, chronic liver dysfunction or cirrhosis, neurocognitive impairment, trichorrhexis nodosa, and systemic hypertension
Personalize your experience
Follow Argininosuccinate lyase deficiency and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.